ArticleOncoimmunology2013
Trial watch: Monoclonal antibodies in cancer therapy.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Dark matter matters: from noncoding RNA regulation to cancer immunity.Oncoimmunology · 2026Review
- Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Digital Pathology for Better Clinical Practice.Cancers · 2024Review
- Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy.Molecular biology reports · 2024Review
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Article
- Article
- Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.Oncoimmunology · 2023Review
- Immune sunrise: from the immunome to the cancer immune landscape.Oncoimmunology · 2022Article
- Evasion before invasion: Pre-cancer immunosurveillance.Oncoimmunology · 2021Article
- License to kill: microsatellite instability and immune contexture.Oncoimmunology · 2021Article
- The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nature reviews. Cancer · 2020Review
- Usefulness and robustness of Immunoscore for personalized management of cancer patients.Oncoimmunology · 2020Review
- Multiverse of immune microenvironment in metastatic colorectal cancer.Oncoimmunology · 2020Article
- Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells.Frontiers in immunology · 2019Article
- Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.Current neurology and neuroscience reports · 2017Review
- Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.British journal of clinical pharmacology · 2016Review
- Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.Emerging microbes & infections · 2016Review
- Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.Oncoimmunology · 2016Article
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.Oncoimmunology · 2016Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past 20 years, dozens-if not hundreds-of monoclonal antibodies have been developed and characterized for their capacity to mediate antineoplastic effects, either as they activate/enhance tumor-specific immune responses, either as they interrupt cancer cell-intrinsic signal transduction cascades, either as they specifically delivery toxins to malignant cells or as they block the tumor-stroma interaction. Such an intense research effort has lead to the approval by FDA of no less than 14 distinct molecules for use in humans affected by hematological or solid malignancies. In the inaugural issue of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.